PepGen Inc. (PEPG)
| Market Cap | 109.55M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -89.66M |
| Shares Out | 69.12M |
| EPS (ttm) | -2.12 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 439,707 |
| Open | 1.580 |
| Previous Close | 1.600 |
| Day's Range | 1.560 - 1.670 |
| 52-Week Range | 1.010 - 7.800 |
| Beta | 2.34 |
| Analysts | Strong Buy |
| Price Target | 11.17 (+604.73%) |
| Earnings Date | May 14, 2026 |
About PEPG
PepGen Inc., a clinical-stage biotechnology company, develops oligonucleotide therapeutics for the treatment of severe neuromuscular and neurologic diseases in the United States. The company engages in the development of PGN-EDODM1, an EDO peptide-conjugated PMO, which is in Phase 2 clinical trial for the treatment of myotonic dystrophy type 1; and FREEDOM2-DM1, which is in Phase 2 for the treatment of myotonic dystrophy type 1. It is also involved in FREEDOM-OLE, an open label expansion study. The company was founded in 2018 and is based in Bo... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 6 analysts, the average rating for PEPG stock is "Strong Buy." The 12-month stock price target is $11.17, which is an increase of 604.73% from the latest price.
News
PepGen Transcript: Study update
The phase II FREEDOM2 study's lowest dose cohort (5 mg/kg) showed a favorable safety profile and promising splicing and vHOT improvements, with one rare outlier affecting group averages. Dose escalation to 10 mg/kg is underway, with results expected in H2 2026.
PepGen Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses
SAN DIEGO, March 31, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential claims on behalf of investors of PepGen Inc. (NASDAQ: PEPG). The investigation focuses on whether PepGen o...
PepGen Announces Topline Results from Lowest Dose (5 mg/kg) MAD Cohort in the Ongoing Phase 2 FREEDOM2 Study Demonstrating Favorable Safety, Splicing and vHOT Data
BOSTON--(BUSINESS WIRE)--PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of se...
PepGen Transcript: Leerink Global Healthcare Conference 2026
Recent data show record splicing improvements in DM1 patients, with ongoing multi-dose studies progressing internationally. Regulatory discussions with the FDA are focused on preclinical findings, while safety and efficacy data continue to support dose escalation and future phase III planning.
US FDA puts partial clinical hold on PepGen's muscle disease drug trial
PepGen said on Wednesday that the U.S. Food and Drug Administration has placed a partial clinical hold on its mid‑stage trial of a rare muscle disease drug, sending its shares plunging over 25% in e...
PepGen Reports Fourth Quarter and Year-End 2025 Financial Results and Recent Corporate Highlights
BOSTON--(BUSINESS WIRE)--PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of se...
PepGen Announces Regulatory Updates on FREEDOM2
BOSTON--(BUSINESS WIRE)--PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies to treat severe neuromuscular and neurological di...
PepGen to Participate in the Leerink Global Healthcare Conference
BOSTON--(BUSINESS WIRE)--PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of se...
PepGen Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Chief Business and Legal Officer
BOSTON--(BUSINESS WIRE)--PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of se...
PepGen Appoints Joseph Vittiglio, Esq., as Chief Business and Legal Officer
BOSTON--(BUSINESS WIRE)--PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of se...
PepGen Transcript: Stifel 2025 Healthcare Conference
Significant splicing improvements were achieved in DM1 patients, with over 50% at the highest dose and no kidney-related adverse events at lower doses. The upcoming MAD study will report 5 mg/kg data in Q1 next year, with expanded geographies to accelerate enrollment.
PepGen Announces Issuance of U.S. Patent for Proprietary PGN-EDODM1 Molecule
BOSTON--(BUSINESS WIRE)--PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of se...
PepGen Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights
BOSTON--(BUSINESS WIRE)--PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of se...
PepGen Transcript: Guggenheim Securities 2nd Annual Healthcare Innovation Conference
Unprecedented splicing improvements and strong safety profile were reported in DM1 trials, with key multiple ascending dose data expected in Q1 and H2 next year. The EDO platform's nuclear delivery and targeted approach drive differentiation, with regulatory and competitive strategies evolving as data matures.
PepGen to Participate in Upcoming Investor Conferences
BOSTON--(BUSINESS WIRE)--PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of se...
PepGen Announces Oral Presentations at the 30th Annual International Congress of the World Muscle Society
BOSTON--(BUSINESS WIRE)--PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of se...
PepGen Announces Closing of Underwritten Public Offering of Common Stock and Exercise in Full of the Underwriters' Option to Purchase Additional Shares
BOSTON,--(BUSINESS WIRE)--PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company developing the next generation of oligonucleotide therapies with the goal of transforming the treatment of ...
PepGen Reports Highest Splicing Correction In Dystrophy Patients, Stock Doubles
PepGen Inc. (NASDAQ: PEPG) stock is skyrocketing on Thursday, with a session volume of 53.04 million compared to the average volume of 943.2 thousand as per data from Benzinga Pro.
PepGen Announces Pricing of $100 Million Public Offering
BOSTON--(BUSINESS WIRE)--PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company developing the next generation of oligonucleotide therapies with the goal of transforming the treatment of s...
PepGen Announces Proposed Public Offering
BOSTON--(BUSINESS WIRE)--PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company developing the next generation of oligonucleotide therapies with the goal of transforming the treatment of s...
PepGen Announces Highest Mean Splicing Correction Reported in DM1 Patients
BOSTON--(BUSINESS WIRE)--PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company developing the next generation of oligonucleotide therapies with the goal of transforming the treatment of s...
PepGen Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights
BOSTON--(BUSINESS WIRE)--PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of se...
SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of PepGen
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In PepGen To Contact Him Directly To Discuss Their Options
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of PepGen
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In PepGen To Contact Him Directly To Discuss Their Options If you suff...
SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of PepGen
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In PepGen To Contact Him Directly To Discuss Their Options If you suff...